-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-07-10
Values as of: 2024-07-10
The investment seeks to track the investment results of Dow Jones U.S. Select Pharmaceuticals Index. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying fund measures the performance of the pharmaceuticals sector of the U.S. equity market and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.
Company Website : www.ishares.com
Currency: USD
Country : USA
Inception Date: 01/05/2006
Primary Benchmark: DJ US Select Pharms TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.44%
Management Expense Ratio: 0.42 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| TARS | Tarsus Pharmaceuticals Inc | 1,000.00 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
-0.55 (-0.37%) |
USD 40.24B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-0.29 (-0.41%) |
USD 3.02B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
-0.32 (-0.29%) |
USD 1.26B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
-0.52 (-0.60%) |
USD 0.25B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
-0.08 (-0.32%) |
USD 0.14B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
+0.33 (+0.90%) |
USD 0.11B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
-1.10 (-1.10%) |
USD 0.08B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
-0.01 (-0.03%) |
USD 0.06B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
-0.03 (-0.05%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
+0.33 (+1.16%) |
USD 0.01B |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 9.21% | 95% | A | 71% | C- | ||
| Dividend Return | 0.92% | 100% | F | 27% | F | ||
| Total Return | 10.13% | 100% | F | 68% | D+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 16.34% | 100% | F | 76% | C+ | ||
| Dividend Return | 1.73% | 100% | F | 27% | F | ||
| Total Return | 18.07% | 100% | F | 74% | C | ||
| Trailing 5 Years | |||||||
| Capital Gain | 37.74% | 57% | F | 69% | C- | ||
| Dividend Return | 7.93% | 94% | A | 27% | F | ||
| Total Return | 45.67% | 67% | D+ | 67% | D+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 6.72% | 43% | F | 63% | D | ||
| Dividend Return | 8.04% | 62% | D | 60% | D- | ||
| Total Return | 1.31% | 100% | F | 31% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 10.24% | 100% | F | 77% | C+ | ||
| Risk Adjusted Return | 78.46% | 76% | C+ | 92% | A | ||
| Market Capitalization | 0.69B | 52% | F | 49% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
